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Abstract Anti-coronavirus disease-2019 (COVID-19; 
anti-severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2)) antibodies against nucleoprotein (NP) 
were purified from pig sera. Following the separation 
of the antibody fraction using a protein-A column, the 
final yield of the purified antibodies against SARS- 
CoV-2 NPs was estimated to be 0.26 ± 0.05 % (abso-
lute amount of 143.4 ± 25.2 ng, n=5) from 1 mL of pig 
sera. The binding activities of the isolated antibodies 
were confirmed using immunoassay and immunos-
taining. Based on the specific binding activity to NPs, 
a quantitative assay was performed using a surface 
plasmon resonance (SPR) biosensor. From the dose- 
response curve, the binding constant (Kd) was calcu-
lated to be 185 pM and the limit of detection was es-
timated to be 1.02 pM. The SPR biosensor with the 
isolated antibodies against SARS-CoV-2 NPs was 
applied for the detection of SARS-CoV-2, MERS- 
CoV, and CoV strain 229E in culture fluid.  
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Coronavirus (CoV) has been classified into four gen-
era: alpha, beta, gamma, and delta, with humans be-
ing infected by the former two coronaviruses1. CoVs 
such as severe acute respiratory syndrome corona-
virus 2 (SARS-CoV-2), SARS-CoV, and Middle East 
respiratory syndrome–related coronavirus (MERS-CoV), 
which are all beta viruses, cause acute respiratory 
diseases such as coronavirus disease-2019 (COVID- 
19), SARS, and MERS, respectively. These beta- 
CoVs also infect pigs (alpha-CoV and beta-CoV), 
dogs (alpha-CoV), cats (alpha-CoV), bats (beta-CoV), 
horses (beta-CoV), and cows (beta-CoV)2. Specifica-
lly, the porcine epidemic diarrhea virus (PEDV; al-
pha-CoV), the transmissible gastroenteritis virus 
(TGEV; alpha-CoV), and the porcine hemagglutinat-
ing encephalomyelitis virus (PHEV; beta-CoV) are 
known to affect pigs.  
The CoV genome encodes for four major structural 
proteins—spike protein, envelope protein, membrane 
protein, and nucleoprotein (NP). Among these, NP is 
known to be highly immunogenic and is abundantly 
expressed during infections3-6. It contains N- and 
C-terminal binding domains with a linkage region. 
As a result, it is frequently used in vaccine develop-
ment and serological assays7. NP enters the host cell 
with viral RNA and participates in viral replication, 
particle assembly, and release8.  
The SARS-CoV-2 NP is 419 amino acid long and has 
a molecular weight of 50 kDa9. The amino acid ho-
mology between SARS-CoV-2 and the pig-infecting 
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beta-CoV was compared for PEDV, TGEV, and 
PHEV using the Basic Local Alignment Search Tool 
(BLAST, https://blast.ncbi.nlm.nih.gov). As summa-
rized in Table 1, we analyzed PHEV (beta-CoV), with 
334 amino acid residues to be 40% identical (amino 
acids) and 55% similar (chemical properties) to 
SARS-CoV-2 NP. The other two pig-infecting alpha- 
CoVs, TGEV and PEDV, were 28% (48%), and 27% 
(40%) identical (similar), respectively. This sequence 
analyses demonstrate the highly homologous amino 
acid sequences across NP in different porcine CoVs 
and that of SARS-CoV-2 (Table 2, 3)10, 11. 
Recently, the purification of antibodies against a 
specific strain of bacteria according to the type of 
lipopolysaccharides (LPS) on the cell membrane was 
reported using the bacteria as an affinity material, and 
the purified antibodies were demonstrated to be used 
for the detection of the specific bacteria strain12. Here, 
we demonstrated the use of SARS-CoV-2 NP as an 
affinity material for the isolation of anti-SARS-CoV- 
2 antibodies from pig sera, to aid in the diagnosis. 
First, SARS-CoV-2 NP, highly homologous with the 
virus affecting pigs was immobilized on magnetic 
beads. The antibodies against SARS- CoV-2 NP were 
isolated from pig sera. The specific binding proper-
ties of the antibodies were then analyzed using imm-
unostaining and immunoassays. Lastly, SARS-CoV-2 
was detected in culture fluid using the surface plas-
mon resonance (SPR) biosensor with the immobi-
lized antibodies. 
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Results and Discussion 
Purification of Anti-SARS-CoV-2 Antibodies from 
Pig Sera 
The anti-SARS-CoV-2 antibodies were purified using 
NPs, which were immobilized on magnetic beads as 
shown in Figure 1(a). After incubation of the magne-
tic beads with immobilized NP in pig sera, the bound 
proteins were dissociated using an acidic treatment. 
The dissociated proteins included antibodies against 
SARS-CoV-2 NP as well as other kinds of proteins. 
We used the protein-A column to separate the IgG 
fraction from the dissociated proteins. The antibody 
fraction was used for further assays. The final yield 
of the purified antibodies against SARS-CoV-2 NP 
was estimated to be 0.26 ± 0.05 % (absolute amount 
of 143.4 ± 25.2 ng, n=5) from 1 mL pig sera, using 
the bicinchoninic acid (BCA) assay method for total 
protein analysis12. 
The purified antibodies against SARS-CoV-2 NP 
were analyzed using sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis (SDS-PAGE). As the 
immunoglobulin G (IgG) has four peptide chains 
connected with disulfide bonds, two heavy chains 
and two light chains could be released by reduction 
of disulfide bonds with a reducing agent of dithio-
threitol (DTT). As shown in Figure 1(b), the protein 
bands from the heavy (molecular weight of 55 kDa) 
and light (molecular weight of 25 kDa) chains were 
observed. For isolated antibodies without the reduc-
tion with DTT, full-length antibodies were observed. 
However, no protein bands from the heavy and light 
chains were observed. These results showed that the 
purified protein, using magnetic beads with immobi-
lized NPs and the protein-A column was a part of the 








Fig. 1. Isolation of antibodies against SARS-CoV-2 NP from pig sera. (a) Isolation procedure of antibodies against SARS-CoV-2 
NP from pig sera using magnetic beads (b) Treatment of the isolated antibody fraction with a reducing agent DTT before and after 
protein-A purification. 
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Binding Properties of Purified Anti-SARS-CoV-2 
Antibodies to NP 
The specific binding property of the isolated anti-
bodies against SARS-CoV-2 NP to NP was estimated 
using an immunoassay and compared across various 
immobilized proteins on the microplate through im-
munostaining the magnetic beads with immobilized 
NP. The immobilized NPs were used for the estima-
tion of the specific binding of isolated antibodies. 
First, five kinds of proteins (SARS-CoV-2 NP, In-
fluenza A/New Caledonia/20/99, Influenza B/Florida/ 
07/04, Influenza B/Tokio/53/99, Hepatitis B virus sur-
face antigen (HBsAg)) were immobilized on a micro-
plate (96-well) and incubated with isolated antibodies 
against SARS-CoV-2 NP. The number of bound an-
tibodies to the NP was measured colorimetrically us-
ing secondary antibodies labeled with horseradish 
peroxidase (HRP) and 3,3', 5,5'-tetramethylbenzidine 
(TMB) as the chromogenic agents. As shown in Figure 
2(a), Influenza B (Florida/Tokio) and HBsAg showed 
30 % greater binding to the isolated antibodies aga-
inst SARS-CoV-2 NP than against NP-coated micro-
plates. Influenza A (New Caledonia) showed no bin-
ding to the isolated antibodies against SARS-CoV-2 
NP. These results demonstrated that the isolated an-
tibodies against SARS-CoV-2 NP were specifically 
binding to NPs. 
To confirm specific binding, we immunostained the 
antibodies using magnetic beads with immobilized 
NPs. The secondary anti-pig IgG labeled with fluore-
scein was treated. As shown in Figure 2(b), the mag-
netic beads with immobilized NP showed a signifi-
cantly higher fluorescence intensity in comparison 
with the BSA coated magnetic beads. These results 
demonstrated that the isolated antibodies against 







Fig. 2. Binding assay of isolated antibodies against SARS-CoV-2 NP from pig sera. (a) Binding assay of the isolated antibodies to 
various antigens immobilized on a microplate. (b) Immunostaining of SARS-CoV-2 NP immobilized on a magnetic bead with the 
isolated antibodies from pig sera. 
6   BioChip J. 
 
 
Quantitative Analysis of SARS-CoV-2 NP Using 
Anti-SARS-CoV-2 Antibodies Derived from Pig 
Sera 
The specific binding properties of the isolated anti-
bodies against SARS-CoV-2 NP were used for the 
quantitative analysis of NPs using SPR biosensor. 
The isolated antibodies against SARS-CoV-2 NP were 
immobilized on the SPR biosensor through covalent 
binding. The gold surface of the SPR biosensor was 
modified to incorporate a carboxylic acid using mer-
captoundecanoic acid. The isolated antibodies were 
covalently bound using the N′-ethylcarbodiimide/ N- 
Hydroxysuccinimide (EDC/NHS) reagent as shown 
in Figure 3(a). The SPR signal for each sample was 
calculated as the change in signal-baseline prior to 
and after sample incubation. The signal-baseline was 
established from the averaged SPR signals following 
three washes. 
The SPR biosensors (Figure 3(b)) were prepared to 












     
(d)
 
Fig. 3. SPR biosensor for the immunoassay of NP using the isolated antibodies against SARS-CoV-2 NP from pig sera. (a) Cova-
lent immobilization of NP to the modified surface of SPR chip. (b) SPR sensorgram for the treatments of the isolated an-
ti-SARS-CoV-2 and anti-CRP antibodies. (c) SPR sensor responses for the treatments of the isolated anti-SARS-CoV-2 NP and an-
ti-CRP antibodies. (d) Dose-response curve from SPR measurements at different concentrations of isolated antibodies against 
SARS-CoV-2 NP from pig sera. 
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CoV-2 and anti-CRP antibodies. Larger SPR signals 
were observed in samples with SARS-CoV-2 anti-
bodies than in samples with anti-CRP antibodies. As 
shown in Figure 3(c), the SPR signals from the anti-
bodies at 100 ng/mL and 1 μg/mL were estimated to 
be 48.3 and 111.3 arbitrary units (AU), respectively. 
In the case of anti-CRP antibodies at the concentra-
tion of 100 ng/mL and 1 μg/mL, the SPR signals were 
estimated to be 3.2 and 11.0 AU, respectively. These 
results showed that the specific binding of the isolat-
ed purified anti-SARS-CoV-2 antibodies to NP could 
be detected using the SPR biosensor. 
We used the SPR biosensor to detect NP by im-
mobilizing the purified anti-SARS-CoV-2 antibodies 
on a modified gold surface. As shown in Figure 3(d), 
the SPR signal was measured for samples of NP at 
the concentration of 2, 5, 10, 20, 50, 100, 200, 500, 
1000 ng/mL. The SPR signal according to the con-
centration of NPs was calculated as mentioned above. 
The dose-response curve for the samples with NPs 









where R (Rmax) represented the SPR signal (maxi-
mum SPR signal), [Ag] represented the NP concen-
tration and Kd represented affinity constant of the 
isolated purified anti-SARS-CoV-2 antibodies to the 
NP. The SPR analysis of NP was possible at the con-
centration range of 2-1000 ng/mL, and the limit of 
detection was estimated to be 1.02 pM from the three 
standard values of averaged baseline signal. From the 
curve fitting based on the isotherm model, the affinity 
constant (Kd) was estimated to be 185 pM. These re-
sults represented that the isolated purified anti- 
SARS-CoV-2 antibodies from pig sera could specifi-
cally bind to NP. The quantitative analyses of NP 
were feasible using the SPR biosensors. 
 
Immunoassay of SARS-CoV-2 Using An-
ti-SARS-CoV-2 Antibodies from Pig Sera 
The feasibility of the medical diagnosis of SARS- 
CoV-2 was tested using the isolated anti-SARS-CoV- 
2 NP antibodies and culture fluid of SARS-CoV-2. 
As the culture fluid of SARS-CoV-2 included the in-
tact virus and NP from the disrupted virus. The SPR 
biosensor was prepared by immobilizing the purified 
anti-SARS-CoV-2 NP antibodies on the modified gold 







   
(c)
 
Fig. 4. SPR biosensor for the immunoassay of SARS-CoV-2 in culture fluid. (a) Immobilization of the isolated antibodies against 
SARS-CoV-2 NP from pig sera to the modified SPR biosensor surface. (b) SPR sensorgram for the treatments of SARS-CoV-2 
culture fluids at different dilution factors. The lateral flow immunoassay for SARS-CoV-2 antigen detection from SD Biosensors 
Co. was used as a reference method. (c) The dose-response curves of the SPR biosensor for the culture fluid of SARS-CoV-2, 
MERS-CoV, CoV strain 229E for the estimation of selectivity. 
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And then, the immunoassay of SARS-CoV-2 in cul-
ture fluid was carried out using the SPR biosensor 
with the immobilized isolated antibodies as shown 
in Figure 4(b). Culture fluids of SARS-CoV-2 with 
dilution factors of 100 (1 %), 333 (0.3 %), 1000 
(0.1 %), 3333 (0.03 %), 10000 (0.01 %) were used as 
standards (Figure 4(b)). For the comparison of the 
sensor response with other types of CoVs, the diluted 
culture fluid of MERS-CoV and CoV strain 229E 
were used as negative samples. For the cutoff estab-
lishment for the medical diagnosis, the lateral flow 
immunoassay for SARS-CoV-2 antigen detection from 
SD Biosensors Co was used as a reference method. 
The cutoff for the determination of a positive SARS- 
CoV-2 test was the culture fluid at a dilution factor of 
927 (0.11 %). As shown in Figure 4(b), the response 
from the SPR biosensor was plotted for the SARS- 
CoV-2 culture fluid at a dilution factor of 10000 
(0.01 %) - 100 (1 %). The cutoff level for the SPR bio-
sensor was estimated to be 171 RU for a known dilu-
tion factor of 927 (0.11 %). These results showed that 
the SPR biosensor with purified antibodies against 
SARS-CoV-2 NP can be used for the detection of 
SARS-CoV-2 in culture fluid at the cutoff level for 
medical diagnoses. As shown in Figure 4(c), the dose- 
response curves for the culture fluid from SARS- 
CoV-2, MERS-CoV, and the CoV strain 229E were 
compared to estimate selectivity. The SARS-CoV-2 
culture fluid had a higher sensitivity than the other 
two strains. The response also showed a quantitative 
increase according to the concentration of SARS-CoV- 
2 culture fluid. The detection range in the SARS- 
CoV-2 culture fluid was established at dilution fac-
tors within the range of 10000 (0.01 %)–100 (1 %). 
The detection limit was estimated to be at a dilution 
factor of 8333 (0.012 %). For MERS-CoV and CoV 
strain 229E, the sensor response was observed to be 
at a baseline level. This low sensitivity to MERS- 
CoV and CoV strain 229E can be explained by the 
amino acid homology. In MERS-CoV, NP had an 
identity (similarity) of 48 % to that of SARS-CoV-2 
NP. CoV strain 229E, an alpha-type CoV, had a rela-
tively low identity (similarity) of 29 % to SARS- 
CoV-2 NP. These results showed that the isolated an-
tibodies against SARS-CoV-2 NP from pig sera 
could be used for the selective detection of this virus. 
 
Conclusions 
In this study, anti-SARS-CoV-2 NP (nucleoprotein) 
was isolated from pig sera without immune-stimu-
lation through the injection of antigen. The basic idea 
of this work was begun from the fact that the amino 
acid homology between SARS-CoV-2 and the pig- 
infecting beta-CoV such as PHEV, TGEV, PEDV had 
a high homology in amino acid sequence. The an-
ti-SARS-CoV-2 antibodies were isolated using NP 
and immobilized on magnetic beads. After the isola-
tion of antibody fraction using protein-A column, the 
final yield of the purified antibodies against SARS- 
CoV-2 NP was estimated to be 0.26 ± 0.05 % (abso-
lute amount of 143.4 ± 25.2 ng, n=5) from 1 mL of 
pig sera. The specific binding properties of purified 
antibodies against SARS-CoV-2 NP were estimated 
using immunoassay and immunostaining. They were 
also quantified using the SPR biosensor. The SPR 
biosensor was feasible within the concentration range 
of 2–1000 ng/mL. The detection limit was estimated 
to be 1.02 pM from three standard values of averaged 
baseline signals. From the curve fitting based on the 
isotherm model, the affinity constant (Kd) was esti-
mated to be 185 pM. These results represented that 
the isolated antibodies against SARS-CoV-2 NP from 
pig sera had specific binding activities to NP. Lastly, 
we used the SPR biosensor with the isolated antibod-
ies to detect SARS-CoV-2, MERS-CoV, and CoV 
strain 229E in culture fluids. The SPR biosensor 
showed that the isolated antibodies against SARS- 
CoV-2 NP from pig sera could be used for selective 
detection of SARS-CoV-2 against MERS-CoV and 
CoV strain 229E. These results showed that the an-
ti-SARS-CoV-2 NP could be isolated from pig sera 
without immune-stimulation and the isolated anti-
body from pig sera could be effectively used for the 
medical diagnosis of anti-SARS-CoV-2 with the se-
lectivity against other corona virus such as MERS- 
CoV and CoV strain 229E. 
 
Materials and Methods 
Materials 
Bovine serum albumin (BSA) and other chemicals 
were purchased from Sigma-Aldrich Korea (Seoul, 
Korea). The anti-pig IgG antibodies labeled with 
horseradish peroxidase (anti-pig(HRP)) or fluoresce-
in (ab9611) were purchased from Abcam (Cambridge, 
UK). The bicinchonic acid (BCA) assay kit, pig sera 
(porcine serum), 3,3’,5,5’-tetramethylbenzidine (TMB) 
reagentwere purchased from Thermo Fisher Scien-
tific (Waltham, MA, USA). The tosyl-activated mag-
netic beads (diameter of 2.8 µm) were purchased from 
Invitrogen Co (Carlsbad, CA, USA). The SARS- 
CoV-2 nucleoprotein (SARS-CoV-2 NP) with the 
His-tag was supplied from Genbody Inc (Cheonan, 
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Korea) and Optolane Inc (Seongnam, Korea), respec-
tively. The influenza viruses (R86380 (A/New cale-
donia/20/99), R01247 (B/Florida/07/04), R86250 (B/ 
Tokio/53/99)) were produced from Meridian Life 
Science Inc (Memphis, TN, USA). Culture fluids of 
SARS-CoV-2, MERS-CoV, CoV strain 229E were 
purchased from Zeptometrix (Buffalo, NY, USA). 
 
Purification of Anti-SARS-CoV-2 Antibodies 
The isolation of antibodies against SARS-CoV-2 NP 
from pig sera was carried out using magnetic beads 
coated with NP via the following steps as shown in 
Fig. 1(a): (1) The pig sera (1 mL) was incubated with 
magnetic beads coated with NP (10 mg of beads) for 
1 h under mild mixing conditions (15 rpm) using a 
wheel-rotating mixer (RT-10, Daehan Scientific Co, 
Wonju, Korea). The NPs were immobilized to the 
tosylactivated magnetic beads by incubation of mag-
netic beads at the amount of 10 mg and NP (800 
μg/mL, 250 μL) for 16 h at 37 °C. (2) The bound 
proteins were dissociated from the magnetic beads 
via treatment with 1 mL of 0.1 M glycine-HCl buffer 
(pH 2.7) for 10 s. Then, the reaction was neutralized 
by the addition of 50 μL of 1 M Tris-HCl buffer (pH 
10.5). (3) For the isolation of antibody fraction, the 
dissociated proteins were loaded onto the protein-A 
column and washed with 10 mL of PBS to any un-
bound proteins. The isolated antibodies against 
SARS-CoV-2 NP were eluted by loading 2 mL of 0.1 
M glycine-HCl buffer (pH 2.7) and directly collected 
in a microcentrifuge tube containing 100 μL of 1 M 
Tris-HCl buffer (pH 10.5). Lastly, the antibodies were 
concentrated via Amicon centrifugal filtration (mo-
lecular weight cutoff: 3 kDa). The yield of antibodies 
was defined as the amount of protein separated from 
a unit volume (1 mL) of pig sera. The amount of pro-
tein was calculated using a BCA assay kit from 
Thermo Fisher Scientific (Waltham, MA, USA). 
 
Binding Assay of Anti-SARS-CoV-2 Antibodies 
The specific binding of the isolated antibodies against 
SARS-CoV-2 NP was estimated using a microplate 
coated with various proteins (Influenza A/New Cal-
edonia/20/99, Influenza B/Florida/07/04, Influenza 
B/Tokio/53/99, Hepatitis B antigen (HBsAg)). The 
immobilization of proteins was achieved by incu-
bating the protein solution (10 μg/mL, 100 μL) for 2 
h at 37 °C in a 96-well microplate. Following this, 
the antibody solution (100 μL) at a concentration of 1 
μg/mL was added to each well for 1 h. The secondary 
antibodies against pig IgG labeled with HRP (100 μL) 
at the concentration of 0.5 μg/mL were incubated for 
1 h. At each change of reagent, the microbeads were 
washed using excess amount (120 μL) of 0.1 % 
Tween 20 in PBS. The colorimetric reaction was 
performed using the TMB reagent (100 μL) for 30 
min. After quenching with 2 M sulfuric acid (100 μL), 
the optical density was measured at the wavelength 
of 450 nm using an ELISA reader (Versamax Micro-
plate reader) from Molecular Devices Co (San Jose, 
CA, USA). 
The immunostaining of magnetic beads with im-
mobilized NP was performed to confirm the specific 
binding of the isolated antibodies against SARS- 
CoV-2 NP. For the immobilization of NP to magnetic 
beads, tosylactivated magnetic beads from Invitrogen 
Co. were incubated with NP at the concentration of 
800 μg/mL for 16 h. For the binding of the isolated 
antibodies from pig sera, NP immobilized magnetic 
beads (1 mg) were incubated with the antibody solu-
tion (500 μL) at the concentration of 1 μg/mL for 1 h. 
The secondary antibodies against pig IgG labeled 
with fluorescein (500 μL) at a concentration of 5 
μg/mL were then incubated for 1 h. At each change 
of reagent, the microbeads were washed using excess 
amounts of 0.1 % Tween 20 in PBS. The fluores-
cence images were taken using a fluorescence mi-
croscope (BX51) from Olympus (Tokyo, Japan)14,15. 
 
SPR Measurement 
An SPR biosensor from i-ClueBio (Sungman, Korea) 
was used for measurements. This biosensor used the 
SPR-chip, which was prepared by sputtering an ad-
hesive layer of titanium (2 nm) and then gold (48 nm) 
onto BK-7 glass (10 × 10 mm2). The isolated anti-
bodies against SARS-CoV-2 NP were immobilized 
on the SPR biosensor through covalent binding. The 
gold surface of SPR biosensor was modified to have 
carboxylic acid by incubating the SPR chip in 1 mM 
mercaptoundecanoic acid for 24 h. For the covalent 
binding of antibodies, the anti- antibodies at the 
concentration 10 μg/mL for 2 h after treatment of 
0.4 M EDC/0.1 M NHS (pH 5.0) for 10 min. The 
SPR biosensor was equipped with a flow cell made 
with a capacity of 50 μL. The samples and the wash-
ing solutions (0.1 % Tween 20 in phosphate buffered 
saline (PBS)) were injected to the flow cell using an 
injection valve and a peristaltic pump. The pumping 
rate was set as 50 μL/min, and the flow of the solu-
tion was programmed to stop during the incubation 
step. SPR signal for each sample was calculated to be 
the change in signal-baselines before and after the 
sample incubation. The signal-baseline was estab-
lished from averaged SPR signals following three 
washes16-18. 
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Estimation of the Limit of Detection 
The SPR signals were fitted with the four parameter 




1 + ( ⁄ )

+  
where a and d are the maximum and minimum SPR 
signal (RU), respectively; c is the concentration of 
SARS-CoV-2 NP (pM); b is Hill’s slope of the curve. 
The limit of detection (LOD) was calculated as the 
concentration of NP at the point of three times of 
standard deviations (SD) above the average baseline 
signal. 
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